Skip to main content

Nuvectis Pharma, Inc. (NVCT)

Nuvectis Pharma will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Capn/a
Revenue (ttm)n/a
Net Income (ttm)-5.97M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About NVCT

Nuvectis Pharma is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious unmet medical needs in oncology. We rely on our core competencies of target selection, drug profiling, and clinical and regulatory execution to build a pipeline of anticancer targeted-therapy drugs. Improved genetic sequencing and understanding of cancers’ RNA, DNA and protein abnormalities has led to the discovery and characterization of novel oncogenic genetic mutations and alterations that were previously...

IndustryBiotechnology
IPO DatePending
CEORon Bentsur, M.B.A.
Employees3
Stock ExchangeNASDAQ
Ticker SymbolNVCT
Full Company Profile

News

Oncology biotech Nuvectis Pharma files for a $30 million IPO

Nuvectis Pharma, a Phase 1-ready biotech developing in-licensed therapies for cancer, filed on Wednesday with the SEC to raise up to $30 million in an initial public offering.

2 weeks ago - Renaissance Capital

Nuvectis Pharma IPO Registration Document (S-1)

Nuvectis Pharma, Inc. has filed to go public with an IPO on the NASDAQ.

2 weeks ago - SEC

Nuvectis Pharma In-Licenses Exclusive Worldwide Rights to a Novel SRC/YES1 Inhibitor (NXP900) from the University of ...

•NXP900 is a SRC/YES1 Kinase Inhibitor with a Novel and Differentiated Mechanism of Action....

1 month ago - GlobeNewswire